This Article Abstract Full Text (PDF) All Versions of this Article: 109/7/898    most recent 01.CIR.0000112605.43318.CAv1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Jain, M. Articles by Liao, R. Search for Related Content PubMed PubMed Citation Articles by Jain, M. Articles by Liao, R. Related Collections Biochemistry and metabolism Energy metabolism Ischemic biology - basic studies Oxidant stress

(Circulation. 2004;109:898-903.)
© 2004 American Heart Association, Inc.

Basic Science Reports

Increased Myocardial Dysfunction After Ischemia-Reperfusion in Mice Lacking Glucose-6-Phosphate Dehydrogenase

Mohit Jain, MD, PhD; Lei Cui, MD; Daniel A. Brenner, MA; Bo Wang, MD; Diane E. Handy, PhD; Jane A. Leopold, MD; Joseph Loscalzo, MD, PhD; Carl S. Apstein, MD; Ronglih Liao, PhD

From the Whitaker Cardiovascular Institute and Evans Department of Medicine, Boston University School of Medicine, Boston, Mass.

Correspondence to Dr Ronglih Liao, Whitaker Cardiovascular Institute, Boston University School of Medicine, 650 Albany St, X-726, Boston, MA 02118. E-mail rliao{at}bu.edu

Received July 1, 2003; de novo received September 13, 2003; revision received October 8, 2003; accepted October 13, 2003.

	Abstract

Top Abstract Introduction Methods Results Discussion References

 
Background— Free radical injury contributes to cardiac dysfunction during ischemia-reperfusion. Detoxification of free radicals requires maintenance of reduced glutathione (GSH) by NADPH. The principal mechanism responsible for generating NADPH and maintaining GSH during periods of myocardial ischemia-reperfusion remains unknown. Glucose-6-phosphate dehydrogenase (G6PD), the rate-limiting enzyme in the pentose phosphate pathway, generates NADPH in a reaction linked to the de novo production of ribose. We therefore hypothesized that G6PD is essential for maintaining GSH levels and protecting the heart during ischemia-reperfusion injury.

Methods and Results— Susceptibility to myocardial ischemia-reperfusion injury was determined in Langendorff-perfused hearts isolated from wild-type mice (WT) and mice lacking G6PD (G6PD^def) (20% of WT myocardial G6PD activity). During global zero-flow ischemia, cardiac function was similar between WT and G6PD^def hearts. On reperfusion, however, cardiac relaxation and contractile performance were greatly impaired in G6PD^def myocardium, as demonstrated by elevated end-diastolic pressures and decreased percent recovery of developed pressure relative to WT hearts. Contractile dysfunction in G6PD^def hearts was associated with depletion of total glutathione stores and impaired generation of GSH from its oxidized form. Increased ischemia-reperfusion injury in G6PD^def hearts was reversed by treatment with the antioxidant MnTMPyP but unaffected by supplementation of ribose stores.

Conclusions— These results demonstrate that G6PD is an essential myocardial antioxidant enzyme, required for maintaining cellular glutathione levels and protecting against oxidative stress-induced cardiac dysfunction during ischemia-reperfusion.

Key Words: ischemia • reperfusion • glucose • free radicals • antioxidants

	Introduction

Top Abstract Introduction Methods Results Discussion References

 
Oxidative stress secondary to free radical generation is an important mechanism of cardiac dysfunction during reperfusion of ischemic myocardium.^1–3 Detoxification of free radicals generated during ischemia-reperfusion is mediated primarily by a highly active intracellular antioxidant defense system, and targeted ablation of antioxidant enzymes predisposes the heart to ischemia-reperfusion injury.⁴ Central to the neutralization of free radicals are endogenous thiol-containing compounds, in particular, the cysteine-containing tripeptide reduced glutathione (GSH).^5,6 GSH allows for the conversion of deleterious hydrogen peroxide and lipid peroxides to water and alcohols, respectively.⁶ Depletion of cardiac GSH exacerbates myocardial ischemia-reperfusion injury,^7–9 whereas exogenous supplementation with GSH protects against such injury.^7,10,11 Generation of GSH from its oxidized form, GSSG, and subsequent maintenance of intracellular GSH pools require reducing equivalents in the form of the pyridine nucleotide NADPH.⁶ Although the importance of NADPH in the cardiac antioxidant system is well established, the mechanisms responsible for generating NADPH during ischemia-reperfusion remain unknown.

Glucose-6-phosphate dehydrogenase (G6PD), the first and rate-limiting enzyme in the pentose phosphate pathway, generates NADPH through a NADP⁺-reduction reaction linked to the oxidation of glucose-6-phosphate and the de novo production of cellular ribose. We have previously shown that G6PD modulates redox status in cardiomyocytes.¹² We therefore hypothesized that G6PD is essential for maintaining myocardial redox homeostasis and protecting the heart from oxidative injury during ischemia-reperfusion. In the present report, we demonstrate that G6PD activity increases rapidly during ischemia-reperfusion in isolated hearts. Furthermore, mice lacking myocardial G6PD exhibit greater sensitivity to ischemia-reperfusion–induced contractile and diastolic dysfunction, associated with depletion of intracellular thiols and loss of redox homeostasis. Finally, increased susceptibility to ischemia-reperfusion injury in G6PD-deficient hearts is found to be primarily a result of increased cellular oxidative stress and independent of de novo ribose production.

	Methods

Top Abstract Introduction Methods Results Discussion References

 
G6PD-Deficient Animals
G6PD-deficient mice (G6PD^def)¹³ were rederived in our laboratories from frozen embryos. G6PD^def mice carry a mutation at the 5' untranslated sequence of the X-linked G6PD gene and, through a splicing defect, exhibit decreased G6PD protein expression and enzyme activity.¹⁴ Mice were genotyped by use of a 2-step procedure to detect a mutation in the DdeI site in the G6PD gene, as previously described.¹⁵ Briefly, DNA was prepared from animal tails, and a 269-bp fragment of the G6PD gene was amplified by polymerase chain reaction (PCR) using the forward primer GGAAACTGGCTGTGCGCTAC and reverse primer TCAGCTCCGGCTCTCTTCTG. The PCR fragment was subsequently digested with the DdeI restriction endonuclease (New England BioLabs), and the restriction digestion products were separated on a 2.5% agarose gel. DdeI enzyme produced bands of 55 and 214 bp in wild-type (WT) mice but did not cleave the mutant G6PD sequence in G6PD^def mice. Hearts from male hemizygous G6PD^def and female homozygous G6PD^def mice exhibited a similar degree of G6PD expression and activity and were therefore grouped and compared with WT littermate controls in this study. All animal studies adhered strictly to the regulations of the Boston University Animal Care Committee and the National Society for Medical Research.

Isolated Heart Perfusion Studies
Hearts were isolated from mice and perfused in the Langendorff mode as previously described.^16,17 Briefly, animals were injected intraperitoneally with heparin (10 000 U/kg) and anesthetized with a mixture of ketamine (150 mg/kg) and xylazine (15 mg/kg). The thorax was rapidly opened and the heart excised and arrested in ice-cold saline. A short perfusion cannula was inserted into the aortic root to initiate retrograde perfusion. The hearts were perfused with Krebs-Henseleit buffer (in mmol/L: NaCl 118, KCl 4.7, CaCl₂ 1.8, KH₂PO₄ 1.2, MgSO₄ 1.2, NaHCO₃ 24.0, and glucose 10.0) equilibrated with 95% O₂/5% CO₂ to yield a pH of 7.4. A thin cannula was pierced through the apex of the left ventricle (LV) to vent thebesian drainage. A ventricular balloon, composed of polyvinyl chloride film and connected to a polyethylene tube, was inserted into the LV through the mitral valve via an incision in the left atrium. The balloon was connected to a pressure transducer (Statham P23Db, Gould) for recording of LV pressures. The balloon was inflated with saline to adjust the end-diastolic pressure (EDP) to 10 mm Hg, and the balloon volume was held constant for the duration of the experiment. Hearts were paced (Grass Instruments) with platinum wires placed on the epicardial surface of the right ventricle. Coronary perfusion pressure was held constant during the duration of the experiment at 80 mm Hg. An inline ultrasonic flow probe (Transonics Systems Inc) was positioned immediately above the aortic cannula to measure coronary flow. Systolic pressure, EDP, and coronary flow were collected online by use of a commercially available data acquisition system (PowerLab ADInstruments). Developed pressure (the difference between systolic and diastolic pressures) and EDP were used as indices of contractile and diastolic function, respectively.

During 20 minutes of baseline stabilization, all hearts were maintained at 37°C and paced at 7 Hz. Hearts were subsequently subjected to 15 minutes of zero-flow ischemia followed by 30 minutes of reperfusion.

For ribose treatment, animals received 100 mg/kg IV of D-ribose (Sigma Chemical Co) in sterile water, a dosage previously determined to supplement myocardial ribose stores.¹⁸ Sixty minutes after treatment, hearts were isolated from animals and subjected to ischemia-reperfusion injury as described above. For antioxidant treatment, isolated hearts were perfused with the superoxide dismutase/catalase mimetic Mn(III)tetrakis(1-methyl-4-pyridyl) porphyrin pentachloride (MnTMPyP)^19,20 (Calbiochem) at a concentration of 50 µmol/L during both baseline and reperfusion periods.

Biochemical Assays
Frozen hearts were homogenized and centrifuged at 16 000g for 15 minutes at 4°C, and the supernatant was collected and used for assays. G6PD activity was determined in homogenates as previously described.¹² Protein concentration was determined according to the method of Lowry et al.²¹ GS_T, GSH, and GSSG concentrations were determined in homogenates by use of a commercially available kit (Cayman Chemical) as previously described.¹² All assays were run in triplicate and averaged to obtain a mean value per sample.

G6PD Immunoblotting
Total G6PD protein levels were determined by standard Western blot. Frozen hearts were homogenized in Triton X-100 lysis buffer (Cell Signaling) with protease inhibitors (2 µmol/L leupeptin, 1 mmol/L PMSF). The lysate was centrifuged at 16 000g for 15 minutes at 4°C. The supernatant was collected, and protein concentration was measured according to the method of Lowry et al.²¹ Samples were run on 12% Tris-glycine precast gels (BioWhittaker) and transferred to polyvinylidene difluoride membranes. Equal protein loading was confirmed by Ponceau staining. After blocking in 5% nonfat milk, polyvinylidene difluoride membranes were probed with rabbit anti-rat G6PD IgG (Bethyl Laboratories Inc) followed by horseradish peroxidase–conjugated anti-rabbit secondary antibody (Pierce Chemical Co). Protein levels were detected by chemiluminescence (Pierce Chemical Co) and quantified by densitometry.

Statistical Analysis
Statistical significance was evaluated by 1-way or 2-way ANOVA. A post hoc test of least significant differences was used to determined differences among groups. All data are expressed as mean±SEM. A probability value of P<0.05 was considered statistically significant.

	Results

Top Abstract Introduction Methods Results Discussion References

 
Activation of G6PD During Ischemia-Reperfusion
To determine whether myocardial G6PD was activated during reperfusion of ischemic myocardium, G6PD activity and protein levels were determined in hearts after ischemia-reperfusion injury. As shown in Figure 1A, ischemia-reperfusion resulted in a 50% increase in myocardial G6PD activity. Increased G6PD activity, however, was not associated with increased expression of G6PD (Figure 1B). These data suggest that G6PD is rapidly activated in response to myocardial ischemia-reperfusion injury, independent of cellular G6PD protein levels.

View larger version (16K): [in this window] [in a new window]   Figure 1. Activation of G6PD during ischemia-reperfusion in isolated hearts. A, G6PD activity and B, protein levels by Western blot at baseline and after ischemia-reperfusion (Post-IR) in isolated hearts (protocol as in Methods). All data represent an average of 4 to 6 individual experiments. *P<0.05 vs baseline. AU, arbitrary units.

Deficiency of G6PD Increases Susceptibility to Ischemia-Reperfusion Injury
To determine the role of G6PD in the myocardial response to ischemia-reperfusion, we used G6PD^def mice. G6PD^def mice carry a mutation at the 5' untranslated sequence of the X-linked G6PD gene and, through a splicing defect, exhibit decreased G6PD expression.¹⁴ WT and G6PD^def genotypes were confirmed in mice via PCR analysis (Figure 2A). As shown in Figure 2B, hearts from G6PD^def mice exhibited decreased expression of G6PD with a corresponding 80% reduction in myocardial G6PD activity (Figure 2C) relative to WT hearts.

View larger version (17K): [in this window] [in a new window]   Figure 2. G6PDdef mice. A, PCR products; B, G6PD protein levels by Western blot; and C, G6PD activity in hearts isolated from WT and G6PDdef mice. All data represent an average of 4 to 6 individual experiments. *P<0.05 vs WT hearts.

WT and G6PD^def hearts were subsequently subjected to ischemia-reperfusion injury. During global zero-flow ischemia, EDP rose in both WT and G6PD^def hearts, with comparable values at peak contracture (WT versus G6PD^def, 74.2±3.6 versus 78.8±5.9 mm Hg, P=NS) and at end-ischemia (WT versus G6PD^def, 69.3±3.1 versus 75.8±4.0 mm Hg, P=NS) (Figure 3A). Over the reperfusion period, however, cardiac relaxation was significantly impaired in G6PD^def hearts, with increased EDP relative to WT hearts (Figure 3A), most pronounced at end reperfusion (WT versus G6PD^def, 33.2±3.4 versus 51.3±3.2 mm Hg, P<0.01). Similarly, contractile performance was also impaired in G6PD^def hearts during reperfusion, with blunted recovery of developed pressure (Figure 3B). Although WT hearts recovered to 60.9±5.0% of baseline developed pressure, G6PD^def hearts recovered to only 40.5±5.7% (P<0.01). Although G6PD^def hearts exhibited greater contractile and diastolic dysfunction during ischemia-reperfusion, coronary flow was similar between WT and G6PD^def hearts at baseline (WT versus G6PD^def, 3.5±0.4 versus 3.7±0.3 mL/min, P=NS) and during the reperfusion period (WT versus G6PD^def, 2.4±0.3 versus 2.3±0.3 mL/min, P=NS) (Figure 3C), suggesting a similar degree of reperfusion-induced vasoconstriction between groups. These data suggest that G6PD is essential in mediating myocardial susceptibility to ischemia-reperfusion injury.

View larger version (28K): [in this window] [in a new window]   Figure 3. Increased susceptibility to myocardial ischemia-reperfusion injury in G6PDdef mice. A, EDP; B, percent recovery of developed pressure; and C, coronary flow in hearts isolated from WT mice (n=10) (open square) and G6PDdef mice (n=7) (closed square) during 15 minutes of zero-flow global ischemia (gray box) and 30 minutes of reperfusion. *P<0.05 vs WT hearts; **P<0.01 vs WT hearts.

Depletion of Cellular Glutathione in G6PD^def Hearts After Ischemia-Reperfusion Injury
To determine whether increased ischemia-reperfusion injury in G6PD^def hearts was associated with depletion of cellular thiols, GS_T, GSH, GSSG, and the GSH/GSSG ratio, a sensitive marker of cellular redox state, were determined in frozen WT and G6PD^def hearts at baseline and after ischemia-reperfusion (Figure 4). In WT hearts at baseline, the vast majority of cellular glutathione was in the reduced state, with a GSH/GSSG ratio greater than 300 (Figure 4D) and with less than 0.3% of GS_T existing as GSSG. Notably, before ischemia-reperfusion, GS_T, GSH, GSSG, and the GSH/GSSG ratio (Figure 4) were comparable between WT and G6PD^def hearts, signifying no baseline oxidative deficit in G6PD^def animals. With ischemia-reperfusion, however, G6PD^def hearts exhibited increased susceptibility to cellular thiol depletion and redox imbalance relative to WT counterparts. In G6PD^def hearts at end-reperfusion, myocardial GS_T (Figure 4A) and GSH (Figure 4B) were decreased to 30% of WT values, with a marked increase in GSSG (Figure 4C) and a corresponding decline in the GSH/GSSG ratio (Figures 4D). Although in WT hearts after ischemia-reperfusion, GSSG composed 0.5±0.1% of GS_T, in G6PD^def hearts, GSSG was 32.9±13.0% of GS_T (P=0.01). These data suggest that deficiency of G6PD exacerbates cellular loss of total thiols and limits regeneration of GSH from its oxidized form during ischemia-reperfusion injury.

View larger version (28K): [in this window] [in a new window]   Figure 4. Depletion of cellular glutathione after myocardial ischemia-reperfusion injury in G6PDdef mice. A, GST; B, GSH; C, GSSG; and D, GSH/GSSG in hearts isolated from WT mice (open bars) and G6PDdef mice (closed bars) at baseline and after ischemia-reperfusion (Post-IR). All data represent an average of 8 to 10 individual experiments. *P<0.05 vs Post-IR WT hearts; P<0.05 vs baseline G6PDdef hearts.

Rescue of Ischemia-Reperfusion Injury in G6PD^def Hearts by Antioxidant Treatment
We subsequently determined whether increased susceptibility to ischemia-reperfusion injury in G6PD^def hearts was secondary to an impairment in cellular redox state or secondary to a decrease in cellular ribose stores. WT and G6PD^def hearts were therefore treated with the superoxide dismutase/catalase mimetic MnTMPyP or animals injected with exogenous ribose, and response to ischemia-reperfusion was examined. Neither MnTMPyP nor ribose treatment altered EDP or contractile function during ischemic conditions (data not shown). Although G6PD functions as the first and rate-limiting enzyme in the de novo production of cellular ribose, supplementation of myocardial ribose stores did not alter ischemia-reperfusion injury in either WT or G6PD^def hearts (Figure 5). In contrast, during reperfusion, treatment with MnTMPyP restored both diastolic function (Figure 5A) and contractile function (Figure 5B) in G6PD^def hearts to WT values. These data suggest that depletion of cellular thiols and exacerbated oxidative stress, rather than impaired de novo production of ribose, are accountable for cardiac dysfunction in G6PD^def hearts during ischemia-reperfusion.

View larger version (18K): [in this window] [in a new window]   Figure 5. Antioxidant rescue of myocardial ischemia-reperfusion injury in G6PDdef mice. A, EDP and B, percent recovery of developed pressure in hearts isolated from WT mice and G6PDdef mice after ischemia-reperfusion and treatment with antioxidant MnTMPyP (50 µmol/L) or D-ribose (100 mg/kg IV) (protocol as in Methods). n=5 to 9 hearts per group. *P<0.01 vs WT hearts; P<0.01 vs Control G6PDdef hearts.

	Discussion

Top Abstract Introduction Methods Results Discussion References

 
In this report, we demonstrate the novel finding that G6PD, the first and rate-limiting enzyme in the pentose phosphate pathway, is essential in maintaining redox homeostasis and protecting against oxidative injury during ischemia-reperfusion in the heart. In response to myocardial ischemia-reperfusion, G6PD is rapidly activated without a change in G6PD protein levels. Mice lacking G6PD exhibited increased cardiac dysfunction during myocardial ischemia-reperfusion, associated with depletion of intracellular glutathione and increased oxidative stress.

Increased G6PD Activity During Myocardial Ischemia-Reperfusion
With ischemia-reperfusion in isolated hearts, a rapid increase in myocardial G6PD activity was observed. A similar increase in G6PD activity has been shown to occur in myocardial tissue during exposure to increased oxidative load,^12,22 suggesting that free radical stress during ischemia-reperfusion may be the stimulus for this phenomenon. The increase in myocardial G6PD activity during ischemia-reperfusion was not associated with a concordant change in G6PD protein levels, consistent with the acute time course. By contrast, more chronic oxidative stressors have been associated with induction of G6PD expression.^23,24 It is therefore likely that during ischemia-reperfusion, G6PD activity is acutely regulated via a posttranslational mechanism. Potential mechanisms may include intracellular translocation, direct oxidative modification, removal of inactivating oligosaccharide groups, and association with intracellular structural elements/stress proteins, all of which have previously been proposed to be important posttranslational regulators of G6PD activity.^12,24–31

Exacerbated Ischemia-Reperfusion Injury in G6PD^def Mice
When subjected to ischemia-reperfusion, hearts isolated from G6PD^def mice exhibited impairment in both diastolic and contractile function relative to WT mice. Notably, cardiac dysfunction in G6PD^def hearts was similar to that of WT counterparts during ischemia and was exacerbated only during the reperfusion period. This finding is concordant with G6PD functioning as an essential antioxidant enzyme, as studies directly measuring free radicals in myocardial tissue have demonstrated only a minimal amount of reactive oxygen or nitrogen species generation occurring during ischemia, with a significant free radical burst on reperfusion.^1,3 Furthermore, increased susceptibility to ischemia-reperfusion injury in G6PD^def animals was similar to the dysfunction observed in mice lacking other previously established antioxidant enzymes, including glutathione peroxidase,^32,33 superoxide dismutase,^34,35 and heme-oxygenase,³⁶ using comparable models of severe zero-flow ischemia and reperfusion in isolated hearts, further supporting an antioxidant role for G6PD. Interestingly, although G6PD has been shown to regulate endothelial cell nitric oxide bioavailability,³⁷ no difference in coronary flow during ischemia-reperfusion was seen in mice lacking G6PD, further implicating a cardiomyocyte-specific pathogenesis for the increased ischemia-reperfusion injury observed in G6PD^def mice.

G6PD deficiency, the most common genetic enzyme disorder, is estimated to affect more than 400 million people worldwide.³⁸ Although G6PD deficiency has long been established to predispose red blood cells to dietary and pharmacological oxidative stressors³⁸ and more recently has been associated with an increased incidence of hypertension and diabetes mellitus,³⁹ it is uncertain whether deficiency of G6PD increases cardiac dysfunction in humans with cardiovascular disease or in other physiologically relevant models of ischemia-reperfusion, although such studies are currently ongoing.

Depletion of Cellular Glutathione in G6PD^def Mice During Ischemia-Reperfusion
Associated with an increase in cardiac dysfunction, G6PD^def hearts exhibited a loss of redox homeostasis during ischemia-reperfusion, marked by both depletion of GS_T and impaired regeneration of GSH from its oxidized form. Depletion of GS_T may represent a loss of intracellular thiols from either passive membrane leakage from damaged cells, formation of higher oxidative states of glutathione, active transport of GSSG from cells, and/or binding of oxidized thiols to intracellular peptides, all of which occur in cardiomyocytes during oxidative stress.^40,41 Depletion of GSH pools and accumulation of GSSG in G6PD^def hearts after ischemia-reperfusion suggest that G6PD is essential for providing the reducing equivalents required to maintain glutathione in its reduced state. Interestingly, at baseline before ischemia-reperfusion, G6PD^def hearts exhibited no deficit in cellular glutathione relative to WT hearts, suggesting either that the residual 20% G6PD activity in G6PD^def hearts was adequate to maintain redox status during baseline conditions or that G6PD may be essential to maintain glutathione levels only during periods of increased oxidative stress.

Impaired diastolic and contractile function in G6PD^def hearts is similar to the cardiac dysfunction that has previously been shown to occur during ischemia-reperfusion with depletion of cellular glutathione^7–9 or with inhibition of glutathione cycling.^32,33 This suggests that G6PD mediates susceptibility to ischemia-reperfusion injury through maintenance of cellular glutathione and protection against oxidative stress. This conclusion is further supported by rescue of G6PD^def hearts by the antioxidant MnTMPyP. Importantly, supplementing myocardial ribose stores did not alter the cardiac response to ischemia-reperfusion in G6PD^def hearts, suggesting that levels of endogenous ribose, the end product of the pentose phosphate pathway, did not influence cardiac function in G6PD^def hearts.

The importance of antioxidant enzymes in protecting against myocardial ischemia-reperfusion injury has been well established previously.⁴ This report demonstrates that G6PD also exists as an essential antioxidant enzyme required for maintaining cellular glutathione levels and protecting against oxidative stress–induced cardiac dysfunction during ischemia-reperfusion.

	Acknowledgments

 
This study was supported by National Heart, Lung, and Blood Institute grants HL-004399 (Dr Leopold); HL-055993, HL-058976, and HL-061795 (Dr Loscalzo); HL-007224 (Dr Apstein); and HL-067297 and HL-073756 (Dr Liao).

	References

Top Abstract Introduction Methods Results Discussion References

 
1. Zweier JL, Flaherty JT, Weisfeldt ML. Direct measurement of free radical generation following reperfusion of ischemic myocardium. Proc Natl Acad Sci U S A. 1987; 84: 1404–1407.[Abstract/Free Full Text]

2. Downey JM. Free radicals and their involvement during long-term myocardial ischemia and reperfusion. Annu Rev Physiol. 1990; 52: 487–504.[CrossRef][Medline] [Order article via Infotrieve]

3. Bolli R, Jeroudi MO, Patel BS, et al. Direct evidence that oxygen-derived free radicals contribute to postischemic myocardial dysfunction in the intact dog. Proc Natl Acad Sci U S A. 1989; 86: 4695–4699.[Abstract/Free Full Text]

4. Das DK, Dillmann W, Ho YS, et al. Using genetically engineered mice to study myocardial ischemia-reperfusion injury. Methods Enzymol. 2002; 353: 346–365.[CrossRef][Medline] [Order article via Infotrieve]

5. Kehrer JP, Lund LG. Cellular reducing equivalents and oxidative stress. Free Radic Biol Med. 1994; 17: 65–75.[CrossRef][Medline] [Order article via Infotrieve]

6. Halliwell B, Gutteridge JMC. Free Radicals in Biology and Medicine. 3rd ed. New York, NY: Oxford University Press; 1999.

7. Singh A, Lee KJ, Lee CY, et al. Relation between myocardial glutathione content and extent of ischemia-reperfusion injury. Circulation. 1989; 80: 1795–1804.[Abstract/Free Full Text]

8. Werns SW, Fantone JC, Ventura A, et al. Myocardial glutathione depletion impairs recovery of isolated blood-perfused hearts after global ischaemia. J Mol Cell Cardiol. 1992; 24: 1215–1220.[CrossRef][Medline] [Order article via Infotrieve]

9. Leichtweis S, Ji LL. Glutathione deficiency intensifies ischaemia-reperfusion induced cardiac dysfunction and oxidative stress. Acta Physiol Scand. 2001; 172: 1–10.[CrossRef][Medline] [Order article via Infotrieve]

10. Gao F, Yao CL, Gao E, et al. Enhancement of glutathione cardioprotection by ascorbic acid in myocardial reperfusion injury. J Pharmacol Exp Ther. 2002; 301: 543–550.[Abstract/Free Full Text]

11. Ferrari R, Ceconi C, Curello S, et al. Oxygen free radicals and myocardial damage: protective role of thiol-containing agents. Am J Med. 1991; 91: 95S–105S.[Medline] [Order article via Infotrieve]

12. Jain M, Brenner DA, Cui L, et al. Glucose-6-phosphate dehydrogenase modulates cytosolic redox status and contractile phenotype in adult cardiomyocytes. Circ Res. 2003; 93: e9–e16.[Abstract/Free Full Text]

13. Pretsch W, Charles DJ, Merkle S. X-linked glucose-6-phosphate dehydrogenase deficiency in Mus musculus. Biochem Genet. 1988; 26: 89–103.[CrossRef][Medline] [Order article via Infotrieve]

14. Sanders S, Smith DP, Thomas GA, et al. A glucose-6-phosphate dehydrogenase (G6PD) splice site consensus sequence mutation associated with G6PD enzyme deficiency. Mutat Res. 1997; 374: 79–87.[Medline] [Order article via Infotrieve]

15. Nicol CJ, Zielenski J, Tsui LC, et al. An embryoprotective role for glucose-6-phosphate dehydrogenase in developmental oxidative stress and chemical teratogenesis. FASEB J. 2000; 14: 111–127.[Abstract/Free Full Text]

16. Jain M, Lim CC, Nagata K, et al. Targeted inactivation of Galpha(i) does not alter cardiac function or beta-adrenergic sensitivity. Am J Physiol. 2001; 280: H569–H575.

17. Lim CC, Liao R, Varma N, et al. Impaired lusitropy-frequency in the aging mouse: role of Ca²⁺-handling proteins and effects of isoproterenol. Am J Physiol. 1999; 277: H2083–H2090.[Medline] [Order article via Infotrieve]

18. Zimmer HG. Restitution of myocardial adenine nucleotides: acceleration by administration of ribose. J Physiol. 1980; 76: 769–775.

19. Faulkner KM, Liochev SI, Fridovich I. Stable Mn(III) porphyrins mimic superoxide dismutase in vitro and substitute for it in vivo. J Biol Chem. 1994; 269: 23471–23476.[Abstract/Free Full Text]

20. Day BJ, Fridovich I, Crapo JD. Manganic porphyrins possess catalase activity and protect endothelial cells against hydrogen peroxide–mediated injury. Arch Biochem Biophys. 1997; 347: 256–262.[CrossRef][Medline] [Order article via Infotrieve]

21. Lowry OJ, Rosebrough NJ, Farr AL, et al. Protein concentration determination. J Biol Chem. 1951; 193: 265–275.[Free Full Text]

22. Zimmer HG, Bunger R, Koschine H, et al. Rapid stimulation on the hexose monophosphate shunt in the isolated perfused rat heart: possible involvement of oxidized glutathione. J Mol Cell Cardiol. 1981; 13: 531–535.[CrossRef][Medline] [Order article via Infotrieve]

23. Ursini MV, Parrella A, Rosa G, et al. Enhanced expression of glucose-6-phosphate dehydrogenase in human cells sustaining oxidative stress. Biochem J. 1997; 323: 801–806.[Medline] [Order article via Infotrieve]

24. Salvemini F, Franze A, Iervolino A, et al. Enhanced glutathione levels and oxidoresistance mediated by increased glucose-6-phosphate dehydrogenase expression. J Biol Chem. 1999; 274: 2750–2757.[Abstract/Free Full Text]

25. Frederiks WM, Bosch KS, De Jong JS, et al. Post-translational regulation of glucose-6-phosphate dehydrogenase activity in (pre)neoplastic lesions in rat liver. J Histochem Cytochem. 2003; 51: 105–112.[Abstract/Free Full Text]

26. Kindzelskii AL, Huang JB, Chaiworapongsa T, et al. Pregnancy alters glucose-6-phosphate dehydrogenase trafficking, cell metabolism, and oxidant release of maternal neutrophils. J Clin Invest. 2002; 110: 1801–1811.[CrossRef][Medline] [Order article via Infotrieve]

27. Guo L, Zhang Z, Green K, et al. Suppression of interleukin-1 beta–induced nitric oxide production in RINm5F cells by inhibition of glucose-6-phosphate dehydrogenase. Biochemistry. 2002; 41: 14726–14733.[CrossRef][Medline] [Order article via Infotrieve]

28. Ozols J. Isolation and the complete amino acid sequence of lumenal endoplasmic reticulum glucose-6-phosphate dehydrogenase. Proc Natl Acad Sci U S A. 1993; 90: 5302–5306.[Abstract/Free Full Text]

29. Swezey RR, Epel D. Regulation of glucose-6-phosphate dehydrogenase activity in sea urchin eggs by reversible association with cell structural elements. J Cell Biol. 1986; 103: 1509–1515.[Abstract/Free Full Text]

30. Stanton RC, Seifter JL, Boxer DC, et al. Rapid release of bound glucose-6-phosphate dehydrogenase by growth factors: correlation with increased enzymatic activity. J Biol Chem. 1991; 266: 12442–12448.[Abstract/Free Full Text]

31. Preville X, Salvemini F, Giraud S, et al. Mammalian small stress proteins protect against oxidative stress through their ability to increase glucose-6-phosphate dehydrogenase activity and by maintaining optimal cellular detoxifying machinery. Exp Cell Res. 1999; 247: 61–78.[CrossRef][Medline] [Order article via Infotrieve]

32. Forgione MA, Cap A, Liao R, et al. Heterozygous cellular glutathione peroxidase deficiency in the mouse: abnormalities in vascular and cardiac function and structure. Circulation. 2002; 106: 1154–1158.[Abstract/Free Full Text]

33. Yoshida T, Maulik N, Engelman RM, et al. Glutathione peroxidase knockout mice are susceptible to myocardial ischemia reperfusion injury. Circulation. 1997; 96 (suppl II): II-216–II-220.

34. Yoshida T, Maulik N, Engelman RM, et al. Targeted disruption of the mouse Sod I gene makes the hearts vulnerable to ischemic reperfusion injury. Circ Res. 2000; 86: 264–269.[Abstract/Free Full Text]

35. Asimakis GK, Lick S, Patterson C. Postischemic recovery of contractile function is impaired in SOD2(+/-) but not SOD1(+/-) mouse hearts. Circulation. 2002; 105: 981–986.[Abstract/Free Full Text]

36. Yoshida T, Maulik N, Ho YS, et al. H(mox-1) constitutes an adaptive response to effect antioxidant cardioprotection: a study with transgenic mice heterozygous for targeted disruption of the Heme oxygenase-1 gene. Circulation. 2001; 103: 1695–1701.[Abstract/Free Full Text]

37. Leopold JA, Cap A, Scribner AW, et al. Glucose-6-phosphate dehydrogenase deficiency promotes endothelial oxidant stress and decreases endothelial nitric oxide bioavailability. FASEB J. 2001; 15: 1771–1773.[Free Full Text]

38. Beutler E. G6PD deficiency. Blood. 1994; 84: 3613–3636.[Free Full Text]

39. Gaskin RS, Estwick D, Peddi R. G6PD deficiency: its role in the high prevalence of hypertension and diabetes mellitus. Ethn Dis. 2001; 11: 749–754.[Medline] [Order article via Infotrieve]

40. Guarnieri C, Fraticelli A, Ventura C, et al. External GSSG enhances intracellular glutathione level in isolated cardiac myocytes. Biochem Biophys Res Commun. 1987; 147: 658–665.[CrossRef][Medline] [Order article via Infotrieve]

41. Ishikawa T, Sies H. Cardiac transport of glutathione disulfide and S-conjugate: studies with isolated perfused rat heart during hydroperoxide metabolism. J Biol Chem. 1984; 259: 3838–3843.[Abstract/Free Full Text]

This article has been cited by other articles:

				S. Pan, C. J. World, C. J. Kovacs, and B. C. Berk Glucose 6-Phosphate Dehydrogenase Is Regulated Through c-Src-Mediated Tyrosine Phosphorylation in Endothelial Cells Arterioscler Thromb Vasc Biol, June 1, 2009; 29(6): 895 - 901. [Abstract] [Full Text] [PDF]

				M. N. Sack Innate Short-Circuiting of Mitochondrial Metabolism in Cardiac Hypertrophy: Identification of Novel Consequences of Enhanced Anaplerosis Circ. Res., March 27, 2009; 104(6): 717 - 719. [Full Text] [PDF]

				K. M. Pound, N. Sorokina, K. Ballal, D. A. Berkich, M. Fasano, K. F. LaNoue, H. Taegtmeyer, J. M. O'Donnell, and E. D. Lewandowski Substrate-Enzyme Competition Attenuates Upregulated Anaplerotic Flux Through Malic Enzyme in Hypertrophied Rat Heart and Restores Triacylglyceride Content: Attenuating Upregulated Anaplerosis in Hypertrophy Circ. Res., March 27, 2009; 104(6): 805 - 812. [Abstract] [Full Text] [PDF]

				J. Kim, K. Y. Kim, H.-S. Jang, T. Yoshida, K. Tsuchiya, K. Nitta, J.-W. Park, J. V. Bonventre, and K. M. Park Role of cytosolic NADP+-dependent isocitrate dehydrogenase in ischemia-reperfusion injury in mouse kidney Am J Physiol Renal Physiol, March 1, 2009; 296(3): F622 - F633. [Abstract] [Full Text] [PDF]

				M. E. Reichelt, L. Willems, B. A. Hack, J. N. Peart, and J. P. Headrick Cardiac and coronary function in the Langendorff-perfused mouse heart model Exp Physiol, January 1, 2009; 94(1): 54 - 70. [Abstract] [Full Text] [PDF]

				D. J. Chess, W. Xu, R. Khairallah, K. M. O'Shea, W. J. Kop, A. M. Azimzadeh, and W. C. Stanley The antioxidant tempol attenuates pressure overload-induced cardiac hypertrophy and contractile dysfunction in mice fed a high-fructose diet Am J Physiol Heart Circ Physiol, December 1, 2008; 295(6): H2223 - H2230. [Abstract] [Full Text] [PDF]

				X. Li, K. Tang, B. Xie, S. Li, and G. J. Rozanski Regulation of Kv4 channel expression in failing rat heart by the thioredoxin system Am J Physiol Heart Circ Physiol, July 1, 2008; 295(1): H416 - H424. [Abstract] [Full Text] [PDF]

				E. Robin, R. D. Guzy, G. Loor, H. Iwase, G. B. Waypa, J. D. Marks, T. L. V. Hoek, and P. T. Schumacker Oxidant Stress during Simulated Ischemia Primes Cardiomyocytes for Cell Death during Reperfusion J. Biol. Chem., June 29, 2007; 282(26): 19133 - 19143. [Abstract] [Full Text] [PDF]

				J. Kim, I. S. Kil, Y. M. Seok, E. S. Yang, D. K. Kim, D. G. Lim, J.-W. Park, J. V. Bonventre, and K. M. Park Orchiectomy Attenuates Post-ischemic Oxidative Stress and Ischemia/Reperfusion Injury in Mice: A ROLE FOR MANGANESE SUPEROXIDE DISMUTASE J. Biol. Chem., July 21, 2006; 281(29): 20349 - 20356. [Abstract] [Full Text] [PDF]

				R. Matsui, S. Xu, K. A. Maitland, R. Mastroianni, J. A. Leopold, D. E. Handy, J. Loscalzo, and R. A. Cohen Glucose-6-Phosphate Dehydrogenase Deficiency Decreases Vascular Superoxide and Atherosclerotic Lesions in Apolipoprotein E-/- Mice Arterioscler Thromb Vasc Biol, April 1, 2006; 26(4): 910 - 916. [Abstract] [Full Text] [PDF]

				W. M. Frederiks, J. van Marle, C. van Oven, B. Comin-Anduix, and M. Cascante Improved Localization of Glucose-6-phosphate Dehydrogenase Activity in Cells with 5-Cyano-2,3-ditolyl-tetrazolium Chloride as Fluorescent Redox Dye Reveals its Cell Cycle-dependent Regulation J. Histochem. Cytochem., January 1, 2006; 54(1): 47 - 52. [Abstract] [Full Text] [PDF]

				R. Matsui, S. Xu, K. A. Maitland, A. Hayes, J. A. Leopold, D. E. Handy, J. Loscalzo, and R. A. Cohen Glucose-6 Phosphate Dehydrogenase Deficiency Decreases the Vascular Response to Angiotensin II Circulation, July 12, 2005; 112(2): 257 - 263. [Abstract] [Full Text] [PDF]

				J. Wilmanski, M. Siddiqi, E. A. Deitch, and Z. Spolarics Augmented IL-10 production and redox-dependent signaling pathways in glucose-6-phosphate dehydrogenase-deficient mouse peritoneal macrophages J. Leukoc. Biol., July 1, 2005; 78(1): 85 - 94. [Abstract] [Full Text] [PDF]

				J. A. Leopold and J. Loscalzo Oxidative Enzymopathies and Vascular Disease Arterioscler Thromb Vasc Biol, July 1, 2005; 25(7): 1332 - 1340. [Abstract] [Full Text] [PDF]

				X. Li, Z. Xu, S. Li, and G. J. Rozanski Redox regulation of Ito remodeling in diabetic rat heart Am J Physiol Heart Circ Physiol, March 1, 2005; 288(3): H1417 - H1424. [Abstract] [Full Text] [PDF]

				Y. Kuramochi, G. M. Cote, X. Guo, N. K. Lebrasseur, L. Cui, R. Liao, and D. B. Sawyer Cardiac Endothelial Cells Regulate Reactive Oxygen Species-induced Cardiomyocyte Apoptosis through Neuregulin-1{beta}/erbB4 Signaling J. Biol. Chem., December 3, 2004; 279(49): 51141 - 51147. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) All Versions of this Article: 109/7/898    most recent 01.CIR.0000112605.43318.CAv1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Jain, M. Articles by Liao, R. Search for Related Content PubMed PubMed Citation Articles by Jain, M. Articles by Liao, R. Related Collections Biochemistry and metabolism Energy metabolism Ischemic biology - basic studies Oxidant stress